Ignite Creation Date:
2025-12-24 @ 10:54 PM
Ignite Modification Date:
2025-12-25 @ 8:22 PM
Study NCT ID:
NCT00072969
Status:
COMPLETED
Last Update Posted:
2008-03-04
First Post:
2003-11-12
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
A Randomized Trial of Recombinant Humanized Anti-IL-2 Receptor Antibody (Daclizumab) Versus Antithymocyte Globulin (ATG) to Treat the Cytopenia of Myelodysplastic Syndrome (MDS)
Sponsor:
National Heart, Lung, and Blood Institute (NHLBI)
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2003-11
Start Date Type:
None
Primary Completion Date:
None
Primary Completion Date Type:
None
Completion Date:
2005-08
Completion Date Type:
None
First Submit Date:
2003-11-12
First Submit QC Date:
None
Study First Post Date:
2003-11-13
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2008-03-03
Last Update Post Date:
2008-03-04
Last Update Post Date Type:
ESTIMATED